Novo Nordisk Won't Reduce UK Research Should Britain Decide to Leave EU
May 12 2016 - 6:57AM
Dow Jones News
By Denise Roland
Novo Nordisk A/S wouldn't reduce its research activities in the
U.K. should the country exit the European Union, according to
company executives.
Jerzy Gruhn, head of the company's European business, said
investment in U.K. research would be unaffected by a vote to leave
the bloc in the June 23 referendum. He said Denmark-based Novo
Nordisk spent GBP43 million on U.K.-based research between 2011 and
2015. That investment related to clinical trials as well as
collaborations with university researchers in the U.K.
"The U.K. has a very strong academic tradition," said Lars
research Sorensen, chief executive, speaking at a press event. "We
have probably over-emphasised U.K. science" over other countries,
he added.
Mr. Sorensen also said a so-called Brexit could benefit the
company as a weaker euro would boost its financial performance.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
May 12, 2016 06:42 ET (10:42 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
